How to Get Rapamycin (Sirolimus) in Oregon

Oregon Telehealth Law and Rapamycin Prescribing

Oregon permits licensed prescribers to evaluate patients and write prescriptions through synchronous telehealth visits. The Oregon Medical Board and the Oregon State Board of Nursing both recognize audio-video consultations as sufficient for establishing a provider-patient relationship, which means an in-person visit is not mandatory before receiving a sirolimus prescription. Oregon House Bill 2508 (2021) codified telehealth parity, and the state has maintained those allowances through 2026.

Any provider licensed in Oregon, or holding a valid Oregon telehealth registration, can prescribe sirolimus after a clinical evaluation. This includes MDs, DOs, nurse practitioners with prescriptive authority, and physician assistants practicing under a collaborative agreement. The prescriber must document a clinical rationale for off-label use, since sirolimus is FDA-approved only for prophylaxis of organ transplant rejection and lymphangioleiomyomatosis (LAM).

Off-label prescribing is legal in all 50 states. The FDA does not regulate the practice of medicine, so a licensed clinician may prescribe any approved drug for a use supported by clinical evidence [1]. The growing body of literature on mTOR inhibition and aging provides the clinical rationale most longevity-focused prescribers cite.

What Clinical Evidence Supports Off-Label Sirolimus Use

The mechanistic case for rapamycin rests on its inhibition of mTOR complex 1, a nutrient-sensing pathway that accelerates cellular aging when chronically activated. In preclinical models, rapamycin extended median lifespan by 9 to 14% in mice across multiple genetic backgrounds, as demonstrated by the NIA Interventions Testing Program [2].

Human data remain early-stage but suggestive. The PEARL trial (Aging Cell, 2024) enrolled healthy older adults and reported that low-dose rapamycin was well-tolerated over a 48-week treatment period, with no serious drug-related adverse events at weekly doses of 5 mg [3]. Participants showed measurable changes in immune and metabolic biomarkers associated with biological aging, including shifts in the CD4:CD8 T-cell ratio. The trial's findings were published with a call for larger, longer confirmatory studies.

An earlier trial by Mannick et al. (2014) in Science Translational Medicine showed that mTOR inhibition with everolimus (a rapamycin analog) improved influenza vaccine response in older adults by approximately 20% relative to placebo [4]. That result prompted broader interest in whether mTOR inhibition could reverse age-related immune decline.

These are not definitive longevity trials. No randomized controlled trial has yet demonstrated that rapamycin extends human lifespan. The evidence supports biological plausibility and short-term safety, which is the basis on which clinicians prescribe it off-label.

Required Labs Before Starting Sirolimus in Oregon

A responsible prescriber will not write a sirolimus prescription without baseline bloodwork. The standard pre-prescribing panel includes:

Complete blood count (CBC). Sirolimus can cause dose-dependent thrombocytopenia, leukopenia, and anemia. The FDA prescribing information lists hematologic toxicity among its boxed warnings for transplant-dose regimens, though weekly low-dose protocols carry substantially lower risk [1].

Comprehensive metabolic panel (CMP). Liver function tests (AST, ALT) and kidney function markers (creatinine, eGFR) establish organ-clearance capacity. Sirolimus is hepatically metabolized via CYP3A4 and should be dose-adjusted or avoided in patients with significant hepatic impairment.

Fasting lipid panel. Rapamycin can raise LDL cholesterol and triglycerides. The PEARL trial confirmed mild lipid elevations in some participants, though levels generally remained within manageable ranges at the 5 mg weekly dose [3]. Patients with baseline dyslipidemia need closer monitoring.

HbA1c or fasting glucose. mTOR inhibition can transiently impair insulin signaling. Monitoring glucose metabolism is standard practice, particularly for patients with prediabetes or metabolic syndrome.

Some providers also request a fasting insulin level and high-sensitivity CRP to establish a broader metabolic baseline. These are optional but useful for tracking treatment response over time.

Oregon has no state-specific lab requirements beyond what federal prescribing standards dictate. Labs can be drawn at any CLIA-certified facility: Quest, Labcorp, or local hospital outpatient labs across Portland, Eugene, Bend, Salem, and Medford all qualify.

How 503A Compounding Pharmacies Work in Oregon

Oregon licenses 503A compounding pharmacies under the Oregon Board of Pharmacy. A 503A pharmacy compounds medications pursuant to a valid, patient-specific prescription. This means the pharmacy fills your prescription individually, not in bulk batches, and the product is made to order.

For sirolimus, compounding pharmacies typically prepare oral capsules at custom doses (commonly 1 mg, 2 mg, 3 mg, 5 mg, or 6 mg). This offers dosing flexibility that commercial tablets (which come in fixed 0.5 mg, 1 mg, and 2 mg strengths) do not.

Oregon-based 503A pharmacies can dispense compounded sirolimus directly to patients within the state. Out-of-state 503A pharmacies may also ship to Oregon patients, provided they hold appropriate non-resident pharmacy licenses with the Oregon Board of Pharmacy. Several national compounding pharmacies that specialize in longevity prescriptions, including those partnered with telehealth platforms, maintain Oregon licensure.

The cost for compounded sirolimus typically ranges from $60 to $150 per month depending on dose and pharmacy. Commercial generic sirolimus (1 mg tablets) through a retail pharmacy with a GoodRx-style coupon runs approximately $30 to $80 for a 30-day supply. Insurance coverage varies.

Oregon Medicaid and Prior Authorization for Sirolimus

Oregon Health Plan (Medicaid) does cover sirolimus, but requires prior authorization (PA). The coverage indication listed in the Oregon Medicaid formulary is prevention of transplant rejection. Off-label longevity use is not a covered indication under the current formulary, so obtaining PA approval for that purpose is unlikely through Medicaid.

For transplant patients, the PA process requires documentation of the transplant type and date, current immunosuppressive regimen, clinical rationale for sirolimus addition or switch, and the prescriber's NPI. The Oregon Health Authority's Drug Use Review program adjudicates PA requests, typically within 24 to 72 hours.

Private insurance in Oregon follows plan-specific formulary rules. Some commercial plans cover generic sirolimus at Tier 3 or Tier 4 for transplant indications. Off-label coverage through private insurance is rare but possible with a letter of medical necessity documenting the clinical rationale.

Most patients using sirolimus for longevity purposes pay out of pocket. This is the norm nationally, not unique to Oregon.

Prescribing Authority in Oregon: MD vs NP vs PA

Oregon grants full prescriptive authority to nurse practitioners (NPs). Since 2023, Oregon NPs have practiced under full practice authority, meaning they do not require physician supervision or a collaborative practice agreement to prescribe controlled or non-controlled medications. Sirolimus is not a controlled substance, so any Oregon-licensed NP can prescribe it independently.

Physician assistants (PAs) in Oregon practice under a collaborative agreement with a supervising physician. Under this agreement, PAs can prescribe sirolimus, and the scope of their prescriptive authority is defined by the collaboration terms. Oregon updated its PA practice act in 2023 to simplify collaborative agreement requirements through the Oregon Medical Board.

MDs and DOs have unrestricted prescriptive authority in Oregon for any FDA-approved medication, including off-label use. There is no additional certification required to prescribe sirolimus specifically.

All three provider types can conduct the prescribing visit via telehealth. The key distinction: NPs and DOs/MDs in Oregon can prescribe independently, while PAs require a collaborative framework.

Step-by-Step Process to Get Sirolimus in Oregon

The typical path from initial inquiry to first dose follows a predictable sequence.

Step 1: Choose a provider. Select a telehealth platform or local provider experienced in off-label rapamycin prescribing. Confirm they hold an active Oregon license.

Step 2: Complete intake. Most telehealth platforms require a medical history questionnaire, current medication list, and a description of your health goals. This takes 10 to 20 minutes.

Step 3: Order labs. The provider will send a lab requisition to a facility near you. Walk-in availability at Oregon Quest and Labcorp locations typically means same-day or next-day blood draws. Results return in 1 to 3 business days.

Step 4: Provider consultation. A synchronous video visit (15 to 30 minutes) reviews your labs, medical history, and the evidence supporting sirolimus use. The provider discusses risks, monitoring expectations, and dosing.

Step 5: Prescription and fulfillment. If clinically appropriate, the provider sends a prescription to a 503A compounding pharmacy or a retail pharmacy. Compounding pharmacies typically ship within 3 to 5 business days. Retail pharmacies may fill the same day if the generic is in stock.

Step 6: Monitoring. Follow-up labs (CBC, CMP, lipid panel) at 4 to 6 weeks after starting, then every 3 to 6 months. Trough levels may be drawn if clinically indicated, though routine trough monitoring is less common at low weekly doses than in transplant protocols.

Total time from initial inquiry to receiving medication: 7 to 14 days for most patients.

Dosing Protocols for Off-Label Longevity Use

Transplant dosing and longevity dosing differ substantially. The FDA-approved transplant regimen starts at 6 mg loading dose followed by 2 mg daily, titrated to maintain trough levels of 12 to 20 ng/mL in combination with cyclosporine [1]. That protocol produces meaningful immunosuppression. It is not what longevity clinicians prescribe.

Off-label longevity protocols typically use 3 to 6 mg once weekly, producing intermittent mTOR inhibition rather than sustained suppression. The PEARL trial used 5 mg weekly and confirmed tolerability at that dose over 48 weeks [3]. Some clinicians start at 1 to 3 mg weekly and titrate upward based on tolerance and lab results.

Weekly dosing is thought to preferentially inhibit mTORC1 (associated with cellular senescence and autophagy) while allowing mTORC2 (associated with insulin signaling and cell survival) to recover between doses. This pharmacokinetic distinction, first proposed by Lamming et al. in Science (2012), is the theoretical basis for the intermittent dosing approach [5].

Drug interactions matter. Sirolimus levels increase significantly with concurrent use of strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, grapefruit juice. Conversely, CYP3A4 inducers like rifampin and St. John's wort reduce sirolimus levels. Your prescriber should review your full medication list before dosing.

Transferring an Existing Sirolimus Prescription to Oregon

Oregon permits prescription transfers from out-of-state pharmacies under standard Board of Pharmacy transfer rules. A retail pharmacy in Oregon can accept a transfer of remaining refills from a pharmacy in another state. The transferring pharmacist contacts the receiving pharmacist directly to verify and complete the transfer.

For compounding prescriptions, the process is slightly different. A 503A prescription is patient-specific and pharmacy-specific. You cannot "transfer" a compounding prescription; your prescriber must issue a new prescription to the Oregon-licensed compounding pharmacy.

If your prescriber is licensed in another state but not in Oregon, they cannot legally prescribe to you once you are an Oregon resident or physically located in Oregon. You will need to establish care with an Oregon-licensed provider or confirm your existing provider holds Oregon licensure.

The exception: providers with an Interstate Medical Licensure Compact (IMLC) license who have added Oregon to their compact states. Oregon is a member of the IMLC, which streamlines multi-state medical licensure.

Safety Monitoring and When to Stop

Ongoing monitoring is non-negotiable. The standard follow-up schedule for off-label sirolimus use includes CBC and CMP every 3 to 6 months, a fasting lipid panel every 6 months, and HbA1c every 6 to 12 months.

Reasons to pause or discontinue therapy include: platelet count dropping below 100,000/µL, LDL cholesterol rising above 190 mg/dL despite statin therapy, recurrent infections (two or more requiring antibiotics within 3 months), oral mucositis that does not resolve with dose reduction, or any newly diagnosed malignancy. The Rapamune prescribing information warns of increased infection risk and possible lymphoma with prolonged immunosuppressive doses [1], though these risks are expected to be lower at weekly dosing.

Mouth sores (aphthous ulcers) are the most commonly reported side effect at longevity doses. They are typically mild, dose-dependent, and resolve with temporary dose reduction or a brief drug holiday.